“Feasibility of Isotoxic Dose-Escalated Radiation Therapy with Bevacizumab for Glioblastoma in PRIDE Trial”

https://pubmed.ncbi.nlm.nih.gov/38116137

The PRIDE trial’s proposed concept of isotoxic dose-escalated radiation therapy for glioblastoma, with the addition of protective concurrent bevacizumab to counteract radiation necrosis risk, appears dosimetrically feasible, given the potential protective effect of bevacizumab.